Search

Your search keyword '"Yokoi, Hideki"' showing total 300 results
Start Over Author "Yokoi, Hideki" Publication Year Range Last 10 years
300 results on '"Yokoi, Hideki"'

2. Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

Author

Muto, Satoru, Matsubara, Takeshi, Inoue, Takamitsu, Kitamura, Hiroshi, Yamamoto, Kazuhiro, Ishii, Taisuke, Yazawa, Masahiko, Yamamoto, Ryohei, Okada, Naoto, Mori, Kiyoshi, Yamada, Hiroyuki, Kuwabara, Takashige, Yonezawa, Atsushi, Fujimaru, Takuya, Kawano, Haruna, Yokoi, Hideki, Doi, Kent, Hoshino, Junichi, and Yanagita, Motoko

Published
2023
Full Text
View/download PDF

6. Genome-wide association study of the risk of chronic kidney disease and kidney-related traits in the Japanese population: J-Kidney-Biobank

Author

Sugawara, Yuka, Hirakawa, Yosuke, Nagasu, Hajime, Narita, Akira, Katayama, Akihiro, Wada, Jun, Shimizu, Miho, Wada, Takashi, Kitamura, Hiromasa, Nakano, Toshiaki, Yokoi, Hideki, Yanagita, Motoko, Goto, Shin, Narita, Ichiei, Koshiba, Seizo, Tamiya, Gen, Nangaku, Masaomi, Yamamoto, Masayuki, and Kashihara, Naoki

Published
2023
Full Text
View/download PDF

15. Transcription factor MafB in podocytes protects against the development of focal segmental glomerulosclerosis

Author

Usui, Toshiaki, Morito, Naoki, Shawki, Hossam H., Sato, Yoshinori, Tsukaguchi, Hiroyasu, Hamada, Michito, Jeon, Hyojung, Yadav, Manoj Kumar, Kuno, Akihiro, Tsunakawa, Yuki, Okada, Risa, Ojima, Takaaki, Kanai, Maho, Asano, Keigo, Imamura, Yuki, Koshida, Ryusuke, Yoh, Keigyou, Usui, Joichi, Yokoi, Hideki, Kasahara, Masato, Yoshimura, Ashio, Muratani, Masafumi, Kudo, Takashi, Oishi, Hisashi, Yamagata, Kunihiro, and Takahashi, Satoru

Published
2020
Full Text
View/download PDF

19. Peritoneal Dialysis Guidelines 2019 Part 1 (Position paper of the Japanese Society for Dialysis Therapy)

Author

Ito, Yasuhiko, Ryuzaki, Munekazu, Sugiyama, Hitoshi, Tomo, Tadashi, Yamashita, Akihiro C., Ishikawa, Yuichi, Ueda, Atsushi, Kanazawa, Yoshie, Kanno, Yoshihiko, Itami, Noritomo, Ito, Minoru, Kawanishi, Hideki, Nakayama, Masaaki, Tsuruya, Kazuhiko, Yokoi, Hideki, Fukasawa, Mizuya, Terawaki, Hiroyuki, Nishiyama, Kei, Hataya, Hiroshi, Miura, Kenichiro, Hamada, Riku, Nakakura, Hyogo, Hattori, Motoshi, Yuasa, Hidemichi, and Nakamoto, Hidetomo

Published
2021
Full Text
View/download PDF

25. Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation

Author

Tamura, Takeshi, Kodama, Takahiro, Sato, Katsuhiko, Murai, Kazuhiro, Yoshioka, Teppei, Shigekawa, Minoru, Yamada, Ryoko, Hikita, Hayato, Sakamori, Ryotaro, Akita, Hirofumi, Eguchi, Hidetoshi, Johnson, Randy L., Yokoi, Hideki, Mukoyama, Masashi, Tatsumi, Tomohide, and Takehara, Tetsuo

Subjects
Pancreatitis -- Genetic aspects -- Development and progression, Protein kinases -- Genetic aspects -- Health aspects, Cellular signal transduction -- Genetic aspects -- Health aspects, Growth factors -- Genetic aspects -- Health aspects, Health care industry
Abstract

The role of PI3K and Hippo signaling in chronic pancreatitis (CP) pathogenesis is unclear. Therefore, we assessed the involvement of these pathways in CP by examining the PI3K and Hippo signaling components PTEN and SAV1, respectively. We observed significant decreases in pancreatic PTEN and SAV1 levels in 2 murine CP models: repeated cerulein injection and pancreatic ductal ligation. Additionally, pancreas-specific deletion of Pten and Sav1 (DKO) induced CP in mice. Pancreatic connective tissue growth factor (CTGF) was markedly upregulated in both CP models and DKO mice, and pancreatic CCAAT/ enhancer-binding protein-[alpha] (CEBPA) expression was downregulated in the CP models. Interestingly, in pancreatic acinar cells (PACs), CEBPA knockdown reduced PTEN and SAV1 and increased CTGF levels in vitro. Furthermore, CEBPA knockdown in PACs induced acinar-to-ductal metaplasia and activation of cocultured macrophages and pancreatic stellate cells. These results were mitigated by CTGF inhibition. CP in DKO mice was also ameliorated by Ctgf gene deletion, and cerulein-induced CP was alleviated by antibody-mediated CTGF neutralization. Finally, we observed significantly decreased PTEN, SAV1, and CEBPA and increased CTGF levels in human CP tissues compared with nonpancreatitis tissues. Taken together, our results indicate that dysregulation of PI3K and Hippo signaling induces CP via CTGF upregulation., Introduction Chronic pancreatitis (CP) is characterized by continuous inflammatory destruction of the pancreas and replacement with fibrotic tissues, leading to the permanent loss of pancreatic function (1). CP is caused [...]

Published
2021
Full Text
View/download PDF

26. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess

Author

Nishio, Haruomi, primary, Ishii, Akira, additional, Yamada, Hiroyuki, additional, Mori, Keita P, additional, Kato, Yukiko, additional, Ohno, Shoko, additional, Handa, Takaya, additional, Sugioka, Sayaka, additional, Ishimura, Takuya, additional, Ikushima, Akie, additional, Inoue, Yui, additional, Minamino, Naoto, additional, Mukoyama, Masashi, additional, Yanagita, Motoko, additional, and Yokoi, Hideki, additional

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 3 from CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Author

Makino, Yuki, primary, Hikita, Hayato, primary, Kodama, Takahiro, primary, Shigekawa, Minoru, primary, Yamada, Ryoko, primary, Sakamori, Ryotaro, primary, Eguchi, Hidetoshi, primary, Morii, Eiichi, primary, Yokoi, Hideki, primary, Mukoyama, Masashi, primary, Hiroshi, Suemizu, primary, Tatsumi, Tomohide, primary, and Takehara, Tetsuo, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 5 from CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Author

Makino, Yuki, primary, Hikita, Hayato, primary, Kodama, Takahiro, primary, Shigekawa, Minoru, primary, Yamada, Ryoko, primary, Sakamori, Ryotaro, primary, Eguchi, Hidetoshi, primary, Morii, Eiichi, primary, Yokoi, Hideki, primary, Mukoyama, Masashi, primary, Hiroshi, Suemizu, primary, Tatsumi, Tomohide, primary, and Takehara, Tetsuo, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 6 from CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Author

Makino, Yuki, primary, Hikita, Hayato, primary, Kodama, Takahiro, primary, Shigekawa, Minoru, primary, Yamada, Ryoko, primary, Sakamori, Ryotaro, primary, Eguchi, Hidetoshi, primary, Morii, Eiichi, primary, Yokoi, Hideki, primary, Mukoyama, Masashi, primary, Hiroshi, Suemizu, primary, Tatsumi, Tomohide, primary, and Takehara, Tetsuo, primary

Published
2023
Full Text
View/download PDF

30. Supplementary materials from CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Author

Makino, Yuki, primary, Hikita, Hayato, primary, Kodama, Takahiro, primary, Shigekawa, Minoru, primary, Yamada, Ryoko, primary, Sakamori, Ryotaro, primary, Eguchi, Hidetoshi, primary, Morii, Eiichi, primary, Yokoi, Hideki, primary, Mukoyama, Masashi, primary, Hiroshi, Suemizu, primary, Tatsumi, Tomohide, primary, and Takehara, Tetsuo, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 2 from CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Author

Makino, Yuki, primary, Hikita, Hayato, primary, Kodama, Takahiro, primary, Shigekawa, Minoru, primary, Yamada, Ryoko, primary, Sakamori, Ryotaro, primary, Eguchi, Hidetoshi, primary, Morii, Eiichi, primary, Yokoi, Hideki, primary, Mukoyama, Masashi, primary, Hiroshi, Suemizu, primary, Tatsumi, Tomohide, primary, and Takehara, Tetsuo, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 1 from CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Author

Makino, Yuki, primary, Hikita, Hayato, primary, Kodama, Takahiro, primary, Shigekawa, Minoru, primary, Yamada, Ryoko, primary, Sakamori, Ryotaro, primary, Eguchi, Hidetoshi, primary, Morii, Eiichi, primary, Yokoi, Hideki, primary, Mukoyama, Masashi, primary, Hiroshi, Suemizu, primary, Tatsumi, Tomohide, primary, and Takehara, Tetsuo, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 4 from CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Author

Makino, Yuki, primary, Hikita, Hayato, primary, Kodama, Takahiro, primary, Shigekawa, Minoru, primary, Yamada, Ryoko, primary, Sakamori, Ryotaro, primary, Eguchi, Hidetoshi, primary, Morii, Eiichi, primary, Yokoi, Hideki, primary, Mukoyama, Masashi, primary, Hiroshi, Suemizu, primary, Tatsumi, Tomohide, primary, and Takehara, Tetsuo, primary

Published
2023
Full Text
View/download PDF

41. PS-BPB05-9: DUAL DELETION OF GUANYLYL CYCLASE-A AND P38 MAPK IN PODOCYTES WITH ALDOSTERONE ADMINISTRATION CAUSES GLOMERULAR INTRACAPILLARY THROMBI

Author

Sugioka, Sayaka, primary, Yamada, Hiroyuki, additional, Ishii, Akira, additional, Kato, Yukiko, additional, Mori, Keita P, additional, Ohno, Shoko, additional, Handa, Takaya, additional, Ikushima, Akie, additional, Ishimura, Takuya, additional, Tokudome, Takeshi, additional, Matsusaka, Taiji, additional, Nebreda, Angel R, additional, Yanagita, Motoko, additional, and Yokoi, Hideki, additional

Published
2023
Full Text
View/download PDF

42. Circulating osteocrin stimulates bone growth by limiting C-type natriuretic peptide clearance

Author

Kanai, Yugo, Yasoda, Akihiro, Mori, Keita P., Watanabe-Takano, Haruko, Nagai- Okatani, Chiaki, Yamashita, Yui, Hirota, Keisho, Ueda, Yohei, Yamauchi, Ichiro, Kondo, Eri, Yamanaka, Shigeki, Sakane, Yoriko, Nakao, Kazumasa, Fujii, Toshihito, Yokoi, Hideki, Minamino, Naoto, Mukoyama, Masashi, Mochizuki, Naoki, and Inagaki, Nobuya

Subjects
Osteoblasts -- Research, Parathyroid hormones -- Research, Natriuretic peptides -- Growth -- Research, Health care industry
Abstract

Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR- C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished in either CNP- or NPR-C-depleted backgrounds, confirming that CNP and NPR-C are indispensable for the bone growth-stimulating effect of OSTN. Interestingly, double-transgenic mice of CNP and OSTN had even higher levels of circulating CNP and additional increases in bone length, as compared with mice with elevated CNP alone. Together, these results support OSTN administration as an adjuvant agent for CNP therapy and provide a potential therapeutic approach for diseases with impaired skeletal growth., Introduction Most bones in mammals are formed through endochondral ossification, in that cartilaginous anlage is formed first and is subsequently replaced by calcified bone tissue (1). Although many signaling pathways, [...]

Published
2017
Full Text
View/download PDF

45. A study of Ta2O5 photonic crystals waveguide for Heat-Assisted Magnetic Recording (HAMR).

Author

Watcharakitchakorn, Orrathai, Choowitsakunlert, Salinee, Silapunt, Rardchawadee, Yokoi, Hideki, and Charlton, Martin

Subjects
PHOTONIC crystals, DIELECTRIC waveguides, HARD disks, TANTALUM oxide, LIGHT sources, WAVEGUIDES, SEMICONDUCTOR lasers
Abstract

The research and development of the light delivery system for Heat-Assisted Magnetic Recording (HAMR), which lowers optical transmitted loss, is still in the spotlight and keeps going. Since the commercial product of hard disk drive (HDD) with HAMR technology has been launched, the important part of HAMR technology, which is optical light delivery or waveguide, still needs to be developed. This paper proposes the study of tantalum pentoxide (Ta2O5) photonic crystal (PhC) waveguide for the HAMR light delivery system. The Ta2O5 PhC waveguides are designed at a 1,360 nm wavelength, which is simply to find a light source such as a diode laser. The PhC waveguide dimensions were calculated following the photonic bandgap (PBG) theory. The Ta2O5 PhC waveguides were fabricated and tested. The transmitted efficiency and waveguide attenuation loss of the PhC waveguide is studied and compared with the reference waveguide, which is a dielectric waveguide. The transmitted efficiency (%) of Ta2O5 PhC and dielectric waveguides are 87.3% and 87.2%, respectively. The waveguide attenuation loss (dB/mm) of the Ta2O5 PhC and the dielectric waveguide are 0.73 and 4.42 dB/mm, respectively. The waveguide attenuation loss can be described by the physical properties of the material used and waveguide structure design. From the experiment results, the optical transmitted efficiency of the Ta2O5 PhC waveguide is greater than 85%, which is acceptable optical performance. The attenuation loss of the Ta2O5 PhC waveguide is better than the dielectric waveguide considering it is a suitable material used and its waveguide structure design. It is also concluded that the Ta2O5 PhC waveguide is promising as the candidate for light delivery waveguide for HAMR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Genome-wide association study of the risk of chronic kidney disease and kidney-related traits in the Japanese population: J-Kidney-Biobank

Author

Sugawara, Yuka, primary, Hirakawa, Yosuke, additional, Nagasu, Hajime, additional, Narita, Akira, additional, Katayama, Akihiro, additional, Wada, Jun, additional, Shimizu, Miho, additional, Wada, Takashi, additional, Kitamura, Hiromasa, additional, Nakano, Toshiaki, additional, Yokoi, Hideki, additional, Yanagita, Motoko, additional, Goto, Shin, additional, Narita, Ichiei, additional, Koshiba, Seizo, additional, Tamiya, Gen, additional, Nangaku, Masaomi, additional, Yamamoto, Masayuki, additional, and Kashihara, Naoki, additional

Published
2022
Full Text
View/download PDF

49. Calcium channel blocker in patients with chronic kidney disease

Author

40760153, 70378769, 90378779, Ohno, Shoko, Ishii, Akira, Yanagita, Motoko, Yokoi, Hideki, 40760153, 70378769, 90378779, Ohno, Shoko, Ishii, Akira, Yanagita, Motoko, and Yokoi, Hideki

Abstract

[Background] Chronic kidney disease (CKD) is involved in a progressive deterioration in renal function over the years and is now a global public health problem. Currently, reducing the number of patients progressing to end-stage renal failure is urgently necessary. Hypertension and CKD interact with each other, and good control of blood pressure (BP) can improve CKD patients’ prognosis. With the current global trend for more strict BP control, the importance of BP management and the need for medication to achieve this strict goal are increasing. Calcium channel blockers (CCBs), which target voltage-dependent calcium channels, are frequently used in combination with renin–angiotensin–aldosterone system inhibitors for CKD patients because of their strong BP-lowering properties and relatively few adverse side effects. Calcium channels have several subtypes, including L, N, T, P/Q, and R, and three types of CCBs, L-type CCBs, L-/T-type CCBs, and L-/N-type CCBs, that are available. Nowadays, the new functions and effects of the CCBs are being elucidated. [Conclusion] We should use different types of CCBs properly depending on their pharmacological effects, such as the strength of antihypertensive effects and the organ protection effects, taking into account the pathophysiology of the patients. In this article, the role and the use of CCBs in CKD patients are reviewed.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results